Patients If GLP-1s work too well, what happens next for metabolic dis... What happens if GLP-1s work too well?
Market Access Fighting fake GLP-1s to protect patients & preserve trust Counterfeit drug promotion is a patient safety, brand equity, and public trust issue.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia last month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Patients Using patient data to fill in GLP-1 blind spots, with Phil J... At Reuters Pharma USA, Evidation Health's Phil Johnson talks about what pharma needs to know about their GLP-1 patients and how better data can help.
R&D BIO-Europe Spring 2026: In conversation with Robert Jacks Robert Jacks, CEO of Sparrow Pharmaceuticals, discusses the company’s work in the cardiometabolic space.
R&D Beyond GLP-1: Preclinical hurdles and solutions for next-gen... The development experience with GLP-1 analogues offers critical insights for navigating ADME challenges in contemporary peptide programmes.
Oncology ASCO 2026: Can a blood test spot cancer early? with Dr Peter... Dr Peter Sasieni, co-investigator for the NHS Galleri trial, discusses advances in population-level blood screening for early cancer detection.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
